Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Blocking MAPK Activation and Immune Checkpoints Reverse Immune Dysfunction and Reduce Disease in a Mouse Model of LCH

Amel Sengal, BS, Meryl Hahne, Jessica Velasquez, Harshal Abhyankar, MS, Thomas Burke, BS, Walter Olea, Robert Reyes, Brooks Scull, MS, Camille Bigenwald, Catherine M. Bollard, MD, Wendong Yu, Miriam Merad, MD, Kenneth L. McClain, MD PhD, Carl E. Allen, MD PhD, Rikhia Chakraborty, PhD

Blood (2019) 134 (Supplement_1): 3602.

https://doi.org/10.1182/blood-2019-128253

Published: 2019

Journal Articles

Genomic Characterization of a Pediatric Cohort with Non-Malignant Lymphoproliferative Disorders

Blood (2019) 134 (Supplement_1): 83.

https://doi.org/10.1182/blood-2019-131884

Published: 2019

Journal Articles

Comprehensive Cell Specific Transcriptome Profiling of a Pediatric Hodgkin Lymphoma Cohort

Jennifer Agrusa, MD, Elmoataz A Abdel Fattah, MBBCh, Howard Lin, BS, Rikhia Chakraborty, PhD, Brooks Scull, MS, Harshal Abhyankar, MS, Nmazuo Wudo Ozuah, MBBS, Olive S. Eckstein, MD, Terzah M Horton, MD PhD, Kala Kamdar, MD, Kenneth L. McClain, MD PhD, Chris Tsz-Kwong Man, PhD, Carl E. Allen, MD PhD

Blood (2019) 134 (Supplement_1): 2773.

https://doi.org/10.1182/blood-2019-125982

Published: 2019

Journal Articles

Inherited Genetic Risk Factors and Langerhans Cell Histiocytosis Relapse Events

Erin Peckham-Gregory, PhD, Michael Scheurer, MPH, PhD, Rikhia Chakraborty, PhD, Harshal Abhyankar, MS, Kenneth L. McClain, MD PhD, Carl E. Allen, MD PhD, Philip J Lupo, PhD

Blood (2018) 132 (Supplement 1): 4278.

https://doi.org/10.1182/blood-2018-99-118743

Published: 2018

Journal Articles

Evaluating Anti-TNF-Alpha Therapy in Patients with Relapsed and Refractory Langerhans Cell Histiocytosis

Thomas Burke, BS, Alejandra Legarreta, MD, Howard Lin, Brooks Scull, Olive S. Eckstein, MD, Kenneth L. McClain, MD PhD, Carl E. Allen, MD PhD

Blood (2018) 132 (Supplement 1): 4941.

https://doi.org/10.1182/blood-2018-99-114295

Published: 2018

Journal Articles

Clinical Outcomes and Molecular Responses in Children with Langerhans Cell Histiocytosis Treated with MAPK Pathway Inhibitors

Olive S. Eckstein, MD, Daniel Zinn, MD, Carolyn Fein Levy, MD, Michael M. Henry, MD, Patrick Campbell, MD, Michael B. Jordan, MD, Ashish R Kumar, MD PhD, Carlos Rodriguez-Galindo, MD PhD, Nobuko Hijiya, MD, Oussama Abla, MD, Kenneth L. McClain, MD PhD, Carl E. Allen, MD PhD

Blood (2018) 132 (Supplement 1): 3684.

https://doi.org/10.1182/blood-2018-99-120393

Published: 2018

Journal Articles

Plasma Inflammatory Protein Profiles Distinguish Hemophagocytic Lymphohistiocytosis from Sepsis and SIRS

Harshal Abhyankar, MS, Carl E. Allen, MD PhD, Howard Lin, Baruch Goldberg, Brooks Scull, Kenneth L. McClain, MD PhD, Jordana Goldman, Trung Nguyen, Michael B. Jordan, MD, Tsz-kwong Man, Olive S. Eckstein, MD, Joseph Lubega, Dalia Bashir, Rikhia Chakraborty, PhD BSc, MSc, Hector Wong, Eyal Muscal, Daniel Zinn, MD

Blood (2017) 130 (Supplement 1): 1011.

https://doi.org/10.1182/blood.V130.Suppl_1.1011.1011

Published: 2017

Journal Articles

Transcriptional Profiles, Lineage Tracing with BRAF-V600E and HLA-DQB2 Expression Support a Model of Blood CD1c+ Cells As Precursors to LCH Lesion CD207+ Cells

Karen Phaik Har Lim, Paul Milne, PhD BSc, Michael Poidinger, PhD, Kaibo Duan, PhD, Howard Lin, Harshal Abhyankar, MS, Daniel Zinn, MD, Olive S. Eckstein, MD, Rikhia Chakraborty, PhD BSc, MSc, Evan Newell, PhD, Miriam Merad, MD, Kenneth L. McClain, MD PhD, Chris Tsz-Kwong Man, PhD, Florent Ginhoux, PhD, Matthew P. Collin, MD PhD, Carl E. Allen, MD PhD

Blood (2017) 130 (Supplement 1): 4218.

https://doi.org/10.1182/blood.V130.Suppl_1.4218.4218

Published: 2017

Journal Articles

Immune Checkpoint Inhibitors Restore Function of Lesion Infiltrating T Lymphocytes in Langerhans Cell Histiocytosis

Rikhia Chakraborty, PhD BSc, MSc, Carl E. Allen, MD PhD, Amel Sengal, BS, Amos S. Gaikwad, PhD, Harshal Abhyankar, MS, Brooks Scull, Olive S. Eckstein, MD, Miriam Merad, MD, Kenneth L. McClain, MD PhD

Blood (2017) 130 (Supplement 1): 2280.

https://doi.org/10.1182/blood.V130.Suppl_1.2280.2280

Published: 2017

Journal Articles

An Evaluation of Parental and Perinatal Characteristics and Risk of Langerhans Cell Histiocytosis in Texas Identifies Risk Disparities By Racial/Ethnic Group

Erin Peckham-Gregory, PhD MPH, Michael Scheurer, MPH, PhD, Kenneth L. McClain, MD PhD, Carl E. Allen, MD PhD, Philip J Lupo, PhD

Blood (2017) 130 (Supplement 1): 4187.

https://doi.org/10.1182/blood.V130.Suppl_1.4187.4187

Published: 2017

Journal Articles

BRAF-V600E in Peripheral Mononuclear Cells and Microglia-like Brain Cells Suggest Hematopoietic Origin of Langerhans Cell Histiocytosis-Associated Neurodegeneration

Blood (2017) 130 (Supplement 1): 2930.

https://doi.org/10.1182/blood.V130.Suppl_1.2930.2930

Published: 2017

Journal Articles

Elevated Ferritin Predicts for Inferior Survival in Patients with Acute Leukemia and May be an Early Marker of a Underlying Systemic Pathologic Inflammation

Blood (2016) 128 (22): 2791.

https://doi.org/10.1182/blood.V128.22.2791.2791

Published: 2016

Journal Articles

Efficacy and Toxicity Profile of Clofarabine in Patients with Recurrent/Refractory Langerhans Cell Histiocytosis and Other Histiocytic Disorders

Olive S. Eckstein, MD, Racheal Bingham, CPNP, Erin Christine Peckham, PhD MPH, Austin Brown, MPH, PhD, Carl E. Allen, MD PhD, Kenneth L. McClain, MD PhD

Blood (2016) 128 (22): 1329.

https://doi.org/10.1182/blood.V128.22.1329.1329

Published: 2016

Journal Articles

A Genome-Wide Assessment of Inherited Genetic Variants and the Risk of Langerhans Cell Histiocytosis

Erin Peckham, PhD, Philip J Lupo, PhD MPH, Michael E Scheurer, PhD MPH, Rikhia Chakraborty, PhD BSc, MSc, John Belmont, MDPhD, Spiridon Tsavachidis, MS, Albert Shih, BS, Harshal Abhyankar, MS, Karen Phaik Har Lim, MS, Brooks Scull, MS, Kenneth L. McClain, MD PhD, Carl Allen, MD PhD

Blood (2015) 126 (23): 4059.

https://doi.org/10.1182/blood.V126.23.4059.4059

Published: 2015

Journal Articles

Evaluation Of Afuresertib, An Oral Pan-AKT Inhibitor, In Patients With Langerhans Cell Histiocytosis

Robert J. Arceci, M.D., Ph.D., Carl E. Allen, MD, PhD, Ira Dunkel, M.D., Eric D. Jacobsen, MD, James Whitlock, Robert Vassallo, M.D., Ivan M. Borrello, MD, Allen Oliff, MD, Shannon R. Morris, MD, PhD, Beth Ann M Reedy, Alison Portnoy, Deborah A. Smith, PharmD, Bob Noble, Amy A. Murnane, Stephen A. Szabo, Carlos Rodriguez-Galindo, Mark L. Heaney, MD, PhD, Kenneth L. McClain, MD, PhD, Sarah Vaseilbuh, MD

Blood (2013) 122 (21): 2907.

https://doi.org/10.1182/blood.V122.21.2907.2907

Published: 2013

Journal Articles

Frequent BRAF V600E Mutations Are Identified in CD207+ Cells in LCH Lesions, but BRAF Status does not Correlate with Clinical Presentation of Patients or Transcriptional Profiles of CD207+ Cells

Tricia L Peters, MD, MS, Tsz-Kwong Chris Man, PhD, Jeremy Price, Renelle George, Phaik Har Lim, MS, Kenneth Matthew Heym, MD, Miriam Merad, MD, PhD, Kenneth L. McClain, MD, PhD, Carl E Allen, MD, PhD

Blood (2011) 118 (21): 1372.

https://doi.org/10.1182/blood.V118.21.1372.1372

Published: 2011

Journal Articles

Langerhans Cells and T Cells in Langerhans Cell Histiocytosis Have Distinct Cytokine and Growth Factor Gene Expression Profiles Depending on the Clinical Risk Groups.

Kenneth L. McClain, MD PhD, Xiao-tian Yan, MD PhD, Liunan Li, MD, John Hicks, MD PhD DDS, Leif E. Peterson, Ph.D.

Blood (2004) 104 (11): 3455.

https://doi.org/10.1182/blood.V104.11.3455.3455

Published: 2004

NARROW

Blocking MAPK Activation and Immune Checkpoints Reverse Immune Dysfunction and Reduce Disease in a Mouse Model of LCH

Genomic Characterization of a Pediatric Cohort with Non-Malignant Lymphoproliferative Disorders

Comprehensive Cell Specific Transcriptome Profiling of a Pediatric Hodgkin Lymphoma Cohort

Inherited Genetic Risk Factors and Langerhans Cell Histiocytosis Relapse Events

Evaluating Anti-TNF-Alpha Therapy in Patients with Relapsed and Refractory Langerhans Cell Histiocytosis

Clinical Outcomes and Molecular Responses in Children with Langerhans Cell Histiocytosis Treated with MAPK Pathway Inhibitors

Plasma Inflammatory Protein Profiles Distinguish Hemophagocytic Lymphohistiocytosis from Sepsis and SIRS

Transcriptional Profiles, Lineage Tracing with BRAF-V600E and HLA-DQB2 Expression Support a Model of Blood CD1c+ Cells As Precursors to LCH Lesion CD207+ Cells

Immune Checkpoint Inhibitors Restore Function of Lesion Infiltrating T Lymphocytes in Langerhans Cell Histiocytosis

An Evaluation of Parental and Perinatal Characteristics and Risk of Langerhans Cell Histiocytosis in Texas Identifies Risk Disparities By Racial/Ethnic Group

BRAF-V600E in Peripheral Mononuclear Cells and Microglia-like Brain Cells Suggest Hematopoietic Origin of Langerhans Cell Histiocytosis-Associated Neurodegeneration

Elevated Ferritin Predicts for Inferior Survival in Patients with Acute Leukemia and May be an Early Marker of a Underlying Systemic Pathologic Inflammation

Efficacy and Toxicity Profile of Clofarabine in Patients with Recurrent/Refractory Langerhans Cell Histiocytosis and Other Histiocytic Disorders

A Genome-Wide Assessment of Inherited Genetic Variants and the Risk of Langerhans Cell Histiocytosis

Evaluation Of Afuresertib, An Oral Pan-AKT Inhibitor, In Patients With Langerhans Cell Histiocytosis

Frequent BRAF V600E Mutations Are Identified in CD207+ Cells in LCH Lesions, but BRAF Status does not Correlate with Clinical Presentation of Patients or Transcriptional Profiles of CD207+ Cells

Langerhans Cells and T Cells in Langerhans Cell Histiocytosis Have Distinct Cytokine and Growth Factor Gene Expression Profiles Depending on the Clinical Risk Groups.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only